![I doser creativity](https://kumkoniak.com/51.jpg)
![i doser creativity i doser creativity](https://www.topbots.com/wp-content/uploads/2017/09/ai_artists_1600px_web-1.jpg)
![i doser creativity i doser creativity](https://idosersoftware.com/images/CreativeThinking_Store.jpg)
Pts are treated with an IT injection of Pexa-Vec alone (1 x 10 9pfu) at Week 1 (W1) Day 1 (D1) followed by 3 IT injections of Pexa-Vec (1 x 10 9pfu) + ipilimumab (4 dose levels: 2.5, 5, 7.5, 10 mg/injection) at W3 D1, W5 D1 and W9 D1. The trial is conducted in pts with at least one injectable lesion (≥2 and ≤8 cm) and one distant non-injected measurable target site. Trial design: ISI-JX is a multicentric, Phase I dose escalation trial followed by an extension part aiming to evaluate the safety, feasibility, and anti-tumor effects of an in situ immunization strategy with IT injections of ipilimumab with Pexa-Vec in adults patients (pts) with solid tumors.
![I doser creativity](https://kumkoniak.com/51.jpg)